Mutual Fund Details
NAV
₹560.9325
as on 22 Nov 2024, 11:20 PM
₹6.3364(1.14%)
Last Change
Scheme Ratings
3
rated by Value Research
Pharma
Rankings based on | as on Invalid date
×
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,70,667
₹1,75,337
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹75,337
Profit (absolute return)
75.34%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 3 months
0.11%
In the last 6 months
15.98%
In the last 1 year
36.45%
In the last 3 years
75.34%
In the last 5 years
251.99%
In the last 10 years
344.80%
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 31 Oct 2024, 05:30 AM
₹8,688.65 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 1% if redeemed within 1 month.
0.91%
Expense Ratio
Plan
Growth
Benchmark
BSE Healthcare Total Return Index
Exit Load
Exit load of 1% if redeemed within 1 month.
Scheme Document
Sectors Holding in this Mutual Fund
as on 31 Oct 2024
Healthcare
95.60%
₹8,306.35 Cr
Cash Holding
4.38%
₹380.56 Cr
Others
0.02%
₹1.74 Cr
Companies Holding in this Mutual Fund
as on 31 Oct 2024
Sun Pharmaceutical Industries Ltd.
13.47%
₹1,170.36 Cr
Divi's Laboratories Ltd.
8.39%
₹728.98 Cr
Lupin Ltd.
7.67%
₹666.42 Cr
Cipla Ltd.
6.20%
₹538.70 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹525.66 Cr
Others
58.22%
₹5,058.53 Cr
View All
View All
This fund's returns:
20.56%Return Duration
3 Years
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.31%
25.52%
3Y Returns
25.52
SBI Healthcare Opportunities Fund Direct Plan-Growth
EquityPharma
Min. Investment
₹500
Category Returns
15.31%
25.52%
3Y Returns
24.40
DSP Healthcare Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
15.31%
25.52%
3Y Returns
23.04
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth is a Equity mutual fund scheme from Nippon India Mutual Fund. This scheme was launched on Invalid date. It has an AUM of ₹8,688.65 Crores and the latest NAV decalared is ₹560.933 as on 23 Nov 2024 at 5:43 pm.
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 36.45%, in last 3 years is 75.34% and 702.88% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹8,688.65 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
View AMC Details
₹5,62,971.15 Cr
AUM
262
Schemes
Address
4th Floor, Tower A, Peninsula Business Park,Ganapatrao Kadam Marg, Lower Parel (W),400013
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
